Asia-Pacific Cancer Therapy Market - Growth, Trends, and Forecasts (2017 - 2022)

The Asia-Pacific market for cancer therapy was estimated at USD 3.65 billion for the year 2014 and is projected to reach USD 7.97 billion by the end of 2020 at a CAGR of 13.9 % during the forecast period from 2014 to 2021.



According to the World Health Organization (WHO), more than 6 million new cancer cases are diagnosed in Asia every year. Cancer is the leading cause of death and the incidence rates are increasing annually. Due to this, the demand for quality cancer treatments has risen dramatically, which is contributing to the growth of the market.



Asia-Pacific Cancer Therapy Market-Market Dynamics



The end-users of this market are clinics, hospitals, and research centers. Lung cancer, breast cancer, colorectal cancer, ovarian cancer, head & neck cancer, stomach cancer and liver cancer are some of the common cancers increasing the treatment options in Asia.



Drivers





Increasing incidence of cancer

Aging population

Growing demand for advanced therapies

Patent expiry of leading drugs

Government initiatives

Increasing public awareness about diseases and treatment options





Restraints





High prices of therapies

Side-effects caused during treatment

Change in reimbursement policies

Stringent regulations





The market for cancer therapy in Asia-Pacific is segmented based on the type of therapy, which includes chemotherapy (marketed drugs and drugs in the pipeline), radiotherapy, surgery, hormone therapy, targeted cancer therapy, immunotherapy (monoclonal antibodies, cancer vaccines, and non-specific immunotherapy) and combination therapy. Chemotherapy, radiation therapy, and combinational therapy are increasingly available in the Asia-Pacific region. However, chemotherapy is the largest segment of APAC cancer therapeutics market.



Many players in this market are trying to expand their product portfolio in order to top the global market. While a few companies are entering the market by acquisitions, top companies are expanding their growth by acquiring other companies. Some companies have adopted product innovation and new product launches as their key business strategy to ensure their dominance in this market. Roche is developing a large number of combinational therapies.



Some of the key players in the market are:





AstraZeneca

Bristol-Myers Squibb

Celgene

Janssen

Merck

Novartis

Pfizer

Teva





Key Deliverables in the Study





Market analysis for the Asia-Pacific cancer therapy market, with region-specific assessments and competition analysis on the global and regional scale.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

Identification and analysis of the macro and micro factors that affect the Asia-Pacific cancer therapy market on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.

Insights on the major countries/regions in which this industry is growing and to also identify the regions that are still untapped.



1. Introduction



1.1 Study Deliverables



1.2 Market Definition



1.3 Sizing Units



1.4 Base Currency



1.5 Review and Forecast Period Years



1.6 General Study Assumptions



2. Research Methodology



2.1 Introduction



2.2 Analysis Methodology



2.3 Econometric Forecast Model



2.4 Research Assumptions



3. Executive Summary



4. Key Inferences



5. Market Overview and Industry Trends



5.1 Current Market Scenario



5.2 Applications of Cancer therapeutics



5.3 Technology Overview



5.4 New Developments



5.5 Industry Value-Chain Analysis



5.6 Product Life-Cycle Analysis



5.7 Product Benchmarking



5.8 Investment Analysis



5.9 PorterFive Forces



5.9.1 Bargaining Power of Suppliers



5.9.2 Bargaining Power of Consumers



5.9.3 Threat of New Entrants



5.9.4 Threat of Substitute Products and Services



5.9.5 Competitive Rivalry within the Industry



6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)



7. Market Drivers



7.1 Increased Incidence of Cancer



7.2 Increasing Public Awareness about Diseases and Treatment Options



7.3 Aging Population



7.4 Rising Government Initiatives



7.5 Growing Demand for Advanced Therapies



7.6 Patent Expiry of Leading Drugs



8. Market Restraints



8.1 High Prices of Therapies



8.2 Side-Effects Caused During Treatment



8.3 Change in Reimbursement Policies



8.4 Stringent Regulatory Issues



9. Key Challenges



10. Current Opportunities in the Market



11. Market Segmentation



11.1 By Type



11.1.1 Chemotherapy



11.1.1.1 Marketed Drugs



11.1.1.2 Drugs in Pipeline



11.1.2 Radiotherapy



11.1.3 Hormone Therapy



11.1.4 Targeted Cancer Therapy



11.1.5 Immunotherapy



11.1.5.1 Monoclonal Antibodies



11.1.5.2 Cancer Vaccines



11.1.5.3 Non-Specific Immunotherapy



11.1.6 Combination Therapy



11.1.7 Surgery



11.2 By Disease



11.2.1 Lung Cancer



11.2.2 Breast Cancer



11.2.3 Colorectal Cancer



11.2.4 Ovarian Cancer



11.2.5 Head and Neck Cancer



11.2.6 Stomach Cancer



11.2.7 Liver Cancer



11.2.8 Others



11.3 By End-User



11.3.1 Hospitals



11.3.2 Clinics



11.3.3 Research Centers



11.4 By Geography



11.4.1 Asia-Pacific



11.4.1.1 Introduction



11.4.1.2 India



11.4.1.3 China



11.4.1.4 Japan



11.4.1.5 Australia & New Zealand



11.4.1.6 South Korea



12. Competitive Landscape



12.1 Merger and Acquisition Analysis



12.2 New Product Launches



12.3 Agreements, Collaborations & Partnerships



13. Company Profiles



13.1 Roche



13.2 Merck



13.3 Bristol-Myers Squibb



13.4 Novartis



13.5 Celgene



13.6 Teva



13.7 Pfizer



13.8 Astra Zeneca



13.9 Janssen



14. Analyst Outlook for Investment Opportunities



15. Future Outlook of the Market

Content are not available

Choose License Type